Whole blood versus red cells and plasma for exchange transfusion in ABO haemolytic disease. 2005

S Yigit, and T Gursoy, and T Kanra, and M Aydin, and G Erdem, and G Tekinalp, and M Yurdakok
Neonatology Unit, Hacettepe University Faculty of Medicine, Ankara, Turkey. suley@hacettepe.edu.tr

Records of 381 neonates who underwent exchange transfusion (ET) due to ABO haemolytic disease at the Division of Neonatology of Hacettepe University, Ankara, Turkey, between January 1977 and December 2003 were reviewed. Records were kept for the type of blood used in ET, the number of ETs for each infant, adverse event attributable to ET and bilirubin levels before, and 4 and 8 h after each ET. Of 381 infants, 300 were transfused with whole blood, whereas 81 infants were transfused with O red cells suspended in A or B plasma. The re-exchange rate was higher in the whole blood group, compared with the erythrocyte and plasma group. Use of erythrocyte and plasma provided 30% reduction in the number of ETs per patient. Eight hours after the first ET, mean bilirubin levels were 84% of the pre-exchange values in the whole blood group and 73% of the pre-exchange values in the erythrocyte and plasma group (P = 0.001). As the use of O group red cells re-suspended in AB plasma decreased the re-exchange risk compared with O group whole blood, we suggest the use of O red cells re-suspended in AB plasma for the ET in cases of ABO haemolytic disease.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008297 Male Males
D010951 Plasma Exchange Removal of plasma and replacement with various fluids, e.g., fresh frozen plasma, plasma protein fractions (PPF), albumin preparations, dextran solutions, saline. Used in treatment of autoimmune diseases, immune complex diseases, diseases of excess plasma factors, and other conditions. Exchange, Plasma,Exchanges, Plasma,Plasma Exchanges
D001803 Blood Transfusion The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed) Blood Transfusions,Transfusion, Blood,Transfusions, Blood
D004899 Erythroblastosis, Fetal A condition characterized by the abnormal presence of ERYTHROBLASTS in the circulation of the FETUS or NEWBORNS. It is a disorder due to BLOOD GROUP INCOMPATIBILITY, such as the maternal alloimmunization by fetal antigen RH FACTORS leading to HEMOLYSIS of ERYTHROCYTES, hemolytic anemia (ANEMIA, HEMOLYTIC), general edema (HYDROPS FETALIS), and SEVERE JAUNDICE IN NEWBORN. Hemolytic Disease of Newborn,Erythroblastosis Fetalis,Erythroblastoses, Fetal,Erythroblastosis Fetali,Fetal Erythroblastoses,Fetal Erythroblastosis,Fetali, Erythroblastosis,Fetalis, Erythroblastosis,Newborn Hemolytic Disease,Newborn Hemolytic Diseases
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000017 ABO Blood-Group System The major human blood type system which depends on the presence or absence of two antigens A and B. Type O occurs when neither A nor B is present and AB when both are present. A and B are genetic factors that determine the presence of enzymes for the synthesis of certain glycoproteins mainly in the red cell membrane. ABH Blood Group,ABO Blood Group,ABO Factors,Blood Group H Type 1 Antigen,H Blood Group,H Blood Group System,ABO Blood Group System,Blood Group, ABH,Blood Group, ABO,Blood Group, H,Blood-Group System, ABO,Factors, ABO,System, ABO Blood-Group
D001663 Bilirubin A bile pigment that is a degradation product of HEME. Bilirubin IX alpha,Bilirubin, (15E)-Isomer,Bilirubin, (4E)-Isomer,Bilirubin, (4E,15E)-Isomer,Bilirubin, Calcium Salt,Bilirubin, Disodium Salt,Bilirubin, Monosodium Salt,Calcium Bilirubinate,Hematoidin,delta-Bilirubin,Bilirubinate, Calcium,Calcium Salt Bilirubin,Disodium Salt Bilirubin,Monosodium Salt Bilirubin,Salt Bilirubin, Calcium,delta Bilirubin
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective

Related Publications

S Yigit, and T Gursoy, and T Kanra, and M Aydin, and G Erdem, and G Tekinalp, and M Yurdakok
October 2001, Vox sanguinis,
S Yigit, and T Gursoy, and T Kanra, and M Aydin, and G Erdem, and G Tekinalp, and M Yurdakok
January 2022, Vox sanguinis,
S Yigit, and T Gursoy, and T Kanra, and M Aydin, and G Erdem, and G Tekinalp, and M Yurdakok
January 1964, Clinica chimica acta; international journal of clinical chemistry,
S Yigit, and T Gursoy, and T Kanra, and M Aydin, and G Erdem, and G Tekinalp, and M Yurdakok
January 1965, Bibliotheca haematologica,
S Yigit, and T Gursoy, and T Kanra, and M Aydin, and G Erdem, and G Tekinalp, and M Yurdakok
July 1974, Indian journal of pediatrics,
S Yigit, and T Gursoy, and T Kanra, and M Aydin, and G Erdem, and G Tekinalp, and M Yurdakok
January 1985, Transfusion,
S Yigit, and T Gursoy, and T Kanra, and M Aydin, and G Erdem, and G Tekinalp, and M Yurdakok
April 1959, Lancet (London, England),
S Yigit, and T Gursoy, and T Kanra, and M Aydin, and G Erdem, and G Tekinalp, and M Yurdakok
April 2023, Transfusion,
S Yigit, and T Gursoy, and T Kanra, and M Aydin, and G Erdem, and G Tekinalp, and M Yurdakok
August 1956, The Medical journal of Australia,
S Yigit, and T Gursoy, and T Kanra, and M Aydin, and G Erdem, and G Tekinalp, and M Yurdakok
January 2018, Asian journal of transfusion science,
Copied contents to your clipboard!